About the 4K Test
The 4Kscore was developed to help aid physicians in determining if their patient with an abnormal prostate specific antigen (PSA) blood test or prostate exam may require a prostate biopsy. The 4Kscore provides a percent risk (ranging from 1-95%) of a patient having aggressive prostate cancer on biopsy. This is computed using several different clinical factors. This test has been shown to be far more accurate than PSA in determining if a patient may have aggressive prostate cancer. Unlike PSA, the 4KScore is not influenced by benign prostate conditions, such as infection or an enlarged prostate.
Below are several resources designed to help patients and their family better understand how the 4KScore is used in a clinical setting, including a video as well as downloadable brochures.